Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL28614671 | 0.93 | TP53 (0.55) | TP53MEN1LMNAKMT2AOR51E2 | |
| Lactic Acid SCHEMBL22346339 | 0.83 | TP53 (0.48) | TP53MEN1LMNAKMT2AOR51E2 | |
| Tromethamine SCHEMBL30296964 | 0.81 | MEN1 (0.53) | TP53MEN1LMNAKMT2AGABRR1 | |
| Deanol SCHEMBL10582731 | 0.79 | TP53 (0.55) | TP53OR51E2GABRR1SLC7A5 | |
| Tromethamine SCHEMBL5524829 | 0.79 | MEN1 (0.50) | TP53MEN1LMNAKMT2AGABRR1 | |
| Threonine SCHEMBL4335256 | 0.77 | SLC7A5 (0.44) | TP53MEN1LMNAKMT2ASLC7A5 | |
| Cadaverine Tartrate SCHEMBL9189378 | 0.77 | TSHR (0.53) | MEN1LMNAKMT2AOR51E2 | |
| Tromethamine SCHEMBL7100590 | 0.76 | LMNA (0.46) | TP53MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL7567125 | 0.75 | LMNA (0.67) | MEN1LMNAKMT2A | |
| Lactic Acid SCHEMBL239851 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014681-A1 | Method for treating dermatoses and tissue damage | RYBACK RALPH (US) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014681-A1 | Method for treating dermatoses and tissue damage | MMP1, COL1A1, COXFA4L2 | TP53 1568/4885MEN1 4382/4885LMNA 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.